October 23, 2016 10:56 AM ET


Company Overview of Neurim Pharmaceuticals (1991) Ltd.

Company Overview

Neurim Pharmaceuticals (1991) Ltd. operates as a drug discovery and development company. It focuses on age-related disorders in the central nervous system. The company provides Circadin, a prolonged release melatonin for insomnia. Its products include orlogin, for circadian rhythm disorders; Neu-120, which has been developed as adjunct therapy to levodopa in patients with motor fluctuations; Neu-P11, a melatonin agonist binds with high affinity to melatonin receptors; and Neu-105 for the treatment of asthma. The company was founded in 1991 and is based in Tel-Aviv, Israel.

8 Hanechoshet St.

Tel-Aviv,  69710


Founded in 1991


972 3 768 4911


972 3 649 4568

Key Executives for Neurim Pharmaceuticals (1991) Ltd.

Founder and President
Age: 74
Founder and Chief Scientific Officer
Chief Operating Officer and Chief Financial Officer
Managing Director
Head of Investor Relations
Compensation as of Fiscal Year 2016.

Neurim Pharmaceuticals (1991) Ltd. Key Developments

Neurim Pharmaceuticals Announces First Patients' Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimer's Disease

Neurim Pharmaceuticals announced that the first patients have been enrolled in the ReCOGNITION study of its novel drug, piromelatine, for Alzheimer's disease (AD). ReCOGNITION is a Phase 2, randomized, placebo controlled, dose ranging study of Piromelatine (5, 20, and 50 mg daily) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to Alzheimer's disease (AD). The 26-week trial will compare once-daily oral doses of Piromelatine to placebo in approximately 500 patients diagnosed with mild AD and treated with stable doses of acetylcholinesterase inhibitors. ReCOGNITION was designed following pre-clinical studies with Piromelatine demonstrating neuroprotection and neurogenesis potential. Additionally, in a previous phase II study Piromelatine demonstrated improvements in sleep maintenance and specifically, enhanced deep, slow-wave, sleep (SWS).

Neurim Pharmaceuticals (1991) Ltd. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016

Neurim Pharmaceuticals (1991) Ltd. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016 . Venue: Grand Hyatt, Tokyo, Japan.

Neurim Pharmaceuticals (1991) Ltd. Presents at BIO-Europe 2015, Nov-02-2015

Neurim Pharmaceuticals (1991) Ltd. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Similar Private Companies By Industry

Company Name Region
Abital Pharma Pipelines Ltd. Middle East/Africa
Active PX Ltd. Middle East/Africa
Advanced Inhalation Technology Ltd. Middle East/Africa
Advanced Inhalation Therapies (AIT) Ltd. Middle East/Africa
Angio B Ltd. Middle East/Africa

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Neurim Pharmaceuticals (1991) Ltd., please visit www.neurim.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.